BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Surpasses Q2 2025 Estimates, Shares Rise in After-Hours Trading
BioMarin Pharmaceutical Inc reported second-quarter 2025 earnings that significantly exceeded analyst expectations, driving a positive market reaction. The company also raised its full-year guidance, reinforcing confidence in its growth trajectory.
Key Earnings Highlights
- Revenue Beat: BioMarin posted Q2 2025 revenues of $825.4 million, a 16% year-over-year increase (17% at constant currency). This comfortably surpassed the consensus estimate of $775.2 million.
- EPS Surge: The company reported GAAP diluted EPS of $1.23, a 124% jump from the prior year. On a non-GAAP basis, EPS came in at $1.44, far exceeding the $0.85 analysts had projected.
- Strong Product Performance: Growth was driven by robust sales across its rare disease portfolio, including Voxzogo (for achondroplasia) and Roctavian (gene therapy for hemophilia A), though specific product breakdowns were not detailed in the release.
Market Reaction
Following the earnings release, BioMarin’s stock rose 4.6% in after-hours trading, reflecting investor optimism. The strong quarterly performance, coupled with upward revisions in guidance, suggests improved profitability and revenue visibility.
Full-Year and Q3 Outlook vs. Analyst Estimates
BioMarin raised its full-year 2025 guidance for:
- Total revenues
- Non-GAAP operating margin
- Non-GAAP diluted EPS
While exact figures weren’t disclosed in the press release, analysts currently expect:
- Full-year 2025 revenue: $3.21 billion
- Full-year 2025 EPS: $3.52
- Q3 2025 revenue estimate: $816.5 million
- Q3 2025 EPS estimate: $0.76
The raised guidance implies management expects to outperform these estimates, which may further support the stock’s upward momentum.
Conclusion
BioMarin’s Q2 results demonstrate accelerating revenue growth and expanding profitability, reinforcing its position as a leader in rare disease therapies. The market’s positive reaction suggests confidence in the company’s ability to sustain this momentum.
For more detailed earnings estimates and historical performance, see BioMarin’s earnings and estimates page.
Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.
